Healio Minute Podcast, Dermatology Edition: Top Headlines - Week of October 16, 2023
Click Here to Manage Email Alerts
In this edition, FDA issues complete response letter for relabotulinumtoxinA; mucocutaneous manifestations may signal COVID-induced inflammatory disease in children and more.
Read the full coverage here:
FDA issues complete response letter for relabotulinumtoxinA for frown lines, crow’s feet
Mucocutaneous manifestations may signal COVID-induced inflammatory disease in children
FDA approves Zoryve for pediatric psoriasis
Colloidal oatmeal, prescription cream comparable in Black children with atopic dermatitis
FDA issues complete response letter for lebrikizumab for eczema treatment
References:
Imam B. Mucocutaneous clinical manifestation of multi-system inflammatory syndrome in children (MIS-C). Presented at: Skin of Color Update; Oct. 6-8, 2023; New York.
Lisante TA, et al. J Dermatolog Treat. 2023;doi:10.1080/09546634.2023.2241587.
Collapse
Click Here to Manage Email Alerts
